Companies
Jinbo Bio-pharmaceutical
the leader in injectable recombinant collagen through its Weiyimei brand of recombinant Type III humanized collagen, reported H1 2025 revenue of RMB 859 million (+42.43% year-on-year) with over 2.7 million units used clinically, though growth decelerated sharply from the 90-180% rates seen in 2023-2024,…
- Country
- China
- Ticker
- 832982.BJ
injectable-filler
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| fibers-textiles | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | RMB 2 billion raised for FAST database and product platform development and working capital replenishment | foodtalks.cn |
| Capacity | 3 million injection-grade products and 50 million units of sterile cosmetics per year in the industrial park | pdf.dfcfw.com |
| Certification | ISO 13485 and ISO 9001 certifications | en.sxjbswyy.com |
| Regulatory approval | Holds three Class III medical device registration certificates in China for recombinant collagen products (including lyophilized fibers, injection solution, and gel) | static.cninfo.com.cn · english.nmpa.gov.cn · pdf.dfcfw.com · foodtalks.cn |
| Production site | Jinbo Synthetic Biology Industrial Park (Shanxi Transformation and Comprehensive Reform Demonstration Zone) | pdf.dfcfw.com |
| Headcount | 823 employees | stock.qianzhan.com |
| Revenue | RMB 859 million for H1 2025 | static.cninfo.com.cn |
Independent sources: en.sxjbswyy.com · english.nmpa.gov.cn · foodtalks.cn · pdf.dfcfw.com · static.cninfo.com.cn · stock.qianzhan.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant collagen for cosmetics | fibers-textiles | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.